People · Operator
Named in public records as an officer, director or promoter · active 2017–2025 · Pharmaceuticals, Biotech / Pharma, Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Ribometrix, Inc. | — | Pharmaceuticals | Series A | $18.5M | $464.6M | 2017 |
| Hyku Biosciences Inc. | — | Biotech / Pharma | Series A | $6.6M | $17.5M | 2025 |
| Endlyz Therapeutics, Inc. | — | Biotechnology | Seed | $3.3M | $81.0M | 2021 |
JOHN GUSTOFSON at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside JOHN GUSTOFSON on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Michael Ross | 1 | 18 |
| Joshua Resnick | 1 | 12 |
| Michael Solomon | 1 | 7 |
| William Marshall | 1 | 6 |
| Jonathan Behr | 1 | 4 |
| Michael Dial | 1 | 4 |
| LAURA BRASS | 1 | 3 |
| Hakan Goker | 1 | 2 |
| KLEEM CHAUDHARY | 1 | 2 |
| Mike Dial | 1 | 2 |
| Katherine Warner | 1 | 1 |
| LAURA TADVALKAR | 1 | 1 |
| MATTHIAS VAN WOENSEL | 1 | 1 |
| Joanna Wolak | 1 | 1 |
| Damian Crowther | 1 | 1 |
| Zaven Kaprielian | 1 | 1 |
| Kevin Weeks | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.